U.S. Markets closed
  • S&P Futures

    4,554.25
    -21.50 (-0.47%)
     
  • Dow Futures

    34,504.00
    -118.00 (-0.34%)
     
  • Nasdaq Futures

    15,896.75
    -91.75 (-0.57%)
     
  • Russell 2000 Futures

    2,182.80
    -22.40 (-1.02%)
     
  • Crude Oil

    67.02
    +0.52 (+0.78%)
     
  • Gold

    1,772.00
    +9.30 (+0.53%)
     
  • Silver

    22.39
    +0.07 (+0.31%)
     
  • EUR/USD

    1.1298
    -0.0008 (-0.0678%)
     
  • 10-Yr Bond

    1.4480
    +0.0140 (+0.98%)
     
  • Vix

    27.95
    -3.17 (-10.19%)
     
  • GBP/USD

    1.3289
    -0.0013 (-0.1010%)
     
  • USD/JPY

    113.1360
    -0.0730 (-0.0645%)
     
  • BTC-USD

    56,312.02
    -726.12 (-1.27%)
     
  • CMC Crypto 200

    1,433.52
    -5.36 (-0.37%)
     
  • FTSE 100

    7,129.21
    -39.47 (-0.55%)
     
  • Nikkei 225

    27,709.69
    -43.68 (-0.16%)
     

Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 23rd Global Investment Conference.

The presentation will be available on-demand via the conference portal and through the Company's website at www.yumanity.com/events beginning at 7 a.m. EDT, September 13.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
rflamm@burnsmc.com / hwong@burnsmc.com
(212) 213-0006 ext. 364 / 316